Up-regulation of proliferating cell nuclear antigen (PCNA) is closely associated with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 130, Issue 2, 2007, Pages 223-231

  Branca, M ^a   Ciotti, M ^b   Giorgi, C ^c   Santini, D ^d   Di Bonito, L ^e   Costa, S ^d   Benedetto, A ^b   Bonifacio, D ^e   Di Bonito, P ^c   Paba, P ^b   Accardi, L ^c   Syrjänen, S ^f   Favalli, C ^b   Syrjanen K ^g  

^a Centro Nazionale di Epidemiologia   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e MAGGIORE HOSPITAL   (Italy)

^f UNIVERSITY OF TURKU   (Finland)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cervical cancer; CIN; CIN treatment; Oncogenic human papillomavirus; PCNA; Persistence; Prognosis; Proliferating cell nuclear antigen; Virus clearance

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; PROTEIN E7;

ADULT; ARTICLE; CANCER GROWTH; CELL CYCLE; DISEASE ASSOCIATION; DNA REPLICATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MANTEL HAENSZEL TEST; MULTIVARIATE ANALYSIS; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

EID: 33846195060     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2006.10.007     Document Type: Article

References (53)

1. Syrjänen K., and Syrjänen S. Papillomavirus infections in human pathology (2000), J. Wiley & Sons, Chichester p. 1-615
2. In: Campo S. (Ed). Papillomavirus research: from natural history to vaccines and beyond (2006), Caister Academic Press, Norwich, UK 1-424
3. Munoz N., Bosch F.X., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
4. Cliffort G.M., Gallus S., Herrero R., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for research on Cancer HPV prevalence surveys: pooled analysis. Lancet 366 (2005) 991-998
5. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 38 (2002) 2229-2242
6. INK4A and Ki-67 in cytologically negative and equivocal pap smears positive for oncogenic human papillomavirus. Int J Gynecol Pathol 24 (2005) 118-124
7. Munger K., Baldwin A., Edwards K.M., et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78 (2004) 11451-11460
8. INK4A expression is related to grade of CIN and high-risk Human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 23 (2004) 354-365
9. Branca M., Ciotti M., Santini D., et al. Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. Am J Clin Pathol 122 (2004) 902-911
10. Fehrman F., and Laiminis L.A. Human papillomaviruses: targeting differentiated epithelial cells for malignant transformation. Oncogene 22 (2003) 5201-5207
11. Heatley M.K. What is the value of proliferation markers in the normal and neoplastic cervix?. Histol Histopathol 13 (1998) 249-254
12. Miyachi K., Frizler M.J., and Tam E.M. Autoantibody to a nuclear antigen in proliferating cells. J Immunol 121 (1978) 2228-2234
13. Bravo R., and Celis J.F. A search for differential polypeptide synthesis throughout the cell cycle of HeLa cells. J Cell Biol 84 (1980) 795-802
14. Kelman Z. PCNA: structure, functions and interactions. Oncogene 14 (1997) 629-640
15. Hingorani M.H., and O'Donnell M. Sliding clamps: a (tail)ored fit. Curr Biol 10 (2000) R25-R29
16. Melendy T., Sedman J., and Stenlund A. Cellular factors required for papillomavirus DNA replication. J Virol 69 12 (1995) 7857-7867
17. Funk J.O., Waga S., Harry J.B., Espling E., Stillman B., and Galloway D.A. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 11 (1997) 2090-2100
18. Jones D.L., Alani R.M., and Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev 11 (1997) 2101-2111
19. Jian Y., Schmidt-Grimminger D.C., Chien W.M., Wu X., Broker T.R., and Chow L.T. Post-transcriptional induction of p21cip1 protein by human papillomavirus E7 inhibits unscheduled DNA synthesis reactivated in differentiated keratinocytes. Oncogene 17 (1998) 2027-2038
20. Noya F., Chien W.M., Wu X., et al. The promoter of the human proliferating cell nuclear antigen gene is not sufficient for cell cycle-dependent regulation in organotypic cultures of keratinocytes. J Biol Chem 277 (2002) 17271-17280
21. Tjalma W., Weyler J., Pollefliet C., et al. The evaluation of proliferative activity in CIN III and microinvasive cervical cancer and its role in recurrence. Eur J Obstet Gynecol Reprod Biol 94 (2001) 270-275
22. Herbsleb M., Knudsen U.B., Orntoft T.F., et al. Telomerase activity, MIB-1, PCNA, HPV 16 and p53 as diagnostic markers for cervical intraepithelial neoplasia. APMIS 109 (2001) 607-617
23. Middleton K., Peh W., Southern S., et al. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol 77 (2003) 10186-10201
24. Astudillo H., Lopez T., Castillo S., Gariglio P., and Benitez L. p53, Bcl-2, PCNA expression, and apoptotic rates during cervical tumorigenesis. Ann N Y Acad Sci 1010 (2003) 771-774
25. Wang J.L., Zheng B.Y., Li X.D., Ångström T., Lindström M.S., and Wallin K.L. Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res 10 (2004) 2407-2414
26. Maeda M.Y., Simoes M., Wakamatsu A., et al. Relevance of the rates of PCNA, Ki-67 and p53 expression according to the epithelial compartment in cervical lesions. Pathologica 93 (2001) 189-195
27. Khaled A., Imamura Y., Noriki S., and Fukuda M. Early progression stage of malignancy of uterine cervical dysplasia as revealed by immunohistochemical demonstration of increased DNA-instability. Eur J Histochem 44 (2000) 143-156
28. Mathevet P., Frappart L., and Hittelman W. Cervix dysplasias: study of Rb and p53 gene expression and correlation with mitotic activity. Gynecol Obstet Fertil 28 (2000) 44-50
29. Xue Y., Feng Y., Zhu G., and Zhang X. Proliferative activity in cervical intraepithelial neoplasia and cervical carcinoma. Chin Med J (Engl) 112 (1999) 373-375
30. Smela M., Chosia M., and Domagala W. Proliferation cell nuclear antigen (PCNA) expression in cervical intraepithelial neoplasia (CIN). An immunohistochemical study. Pol J Pathol 47 (1996) 171-174
31. Amortegui A.J., Meyer M.P., Elborne V.L., and Amin R.M. p53, retinoblastoma gene product, and cyclin protein expression in human papillomavirus virus DNA-positive cervical intraepithelial neoplasia and invasive cancer. Mod Pathol 8 (1995) 907-912
32. Steinbeck R.G., Heselmeyer K.M., Moberger H.B., and Auer G.U. The relationship between proliferating cell nuclear antigen (PCNA), nuclear DNA content and mutant p53 during genesis of cervical carcinoma. Acta Oncol 34 (1995) 171-176
33. Karakitsos P., Kyroudes A., Apostolaki C., et al. The evaluation of PCNA/cyclin expression in cervical intraepithelial lesions. Gynecol Oncol 55 (1994) 101-107
34. Kobayashi I., Matsuo K., Ishibashi Y., Kanda S., and Sakai H. The proliferative activity in dysplasia and carcinoma in situ of the uterine cervix analyzed by proliferating cell nuclear antigen immunostaining and silver-binding argyrophilic nucleolar organizer region staining. Hum Pathol 25 (1994) 198-202
35. Park J.S., Rhyu K.S., Kim C.J., et al. Presence of oncogenic HPV DNAs in cervical carcinoma tissues and pelvic lymph nodes associating with proliferating cell nuclear antigen expression. Gynecol Oncol 60 (1996) 418-423
36. Kotrsova L., Kolar Z., Tichy M., et al. Detection and typing of HPV DNA in situ-improvement in diagnosis of lesions of the uterine cervix. Ceska Gynekol 60 (1995) 231-234
37. Demeter L.M., Stoler M.H., Broker T.R., and Chow L.T. Induction of proliferating cell nuclear antigen in differentiated keratinocytes of human papillomavirus-infected lesions. Hum Pathol 25 (1994) 343-348
38. Tjalma W.A., Weyler J.J., Bogers J.J., et al. The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 97 (2001) 223-230
39. Lenczewski A., Terlikowski S., Sulkowska M., et al. Expression of PCNA antigen in cellular proliferative activity of cervical carcinoma. Ginekol Pol 71 (2000) 1164-1168
40. Oka K., Hoshi T., and Arai T. Prognostic significance of the PC10 index as a prospective assay for cervical cancer treated with radiation therapy alone. Cancer 70 (1992) 1545-1550
41. Branca M., Giorgi C., Santini D., et al. Aberrant expression of vascular endothelial growth factor-C (VEGF-C) is related to grade of cervical intraepithelial neoplasia (CIN) and high-risk Human papillomavirus (HPV), but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer. J Clin Pathol 59 (2006) 40-47
42. Syrjänen K.J. Immunohistochemistry in assessment of molecular pathogenesis of cervical carcinogenesis. Eur J Gynaecol Oncol 26 (2005) 118-124
43. Branca M., Costa S., Mariani L., et al. Assessment of risk factors and Human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS study. Eur J Gynaecol Oncol 25 (2004) 689-698
44. Costa S., Terzano P., Santini D., et al. CD44 isoform 6 (CD44v6) is a prognostic indicators of the response to neoadjuvant chemotherapy in cervical carcinoma. Gynecol Oncol 80 (2001) 67-73
45. Costa S., Terzano P., Santini D., et al. Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis and proliferation as determinants of response to therapy and disease outcome. Am J Clin Pathol 116 (2001) 729-737
46. Costa S., Simone P.D., Venturoli S., et al. Factors predicting human papillomavirus (HPV) clearance in cervical intraepithelial neoplasia (CIN) lesions treated by conization. Gynecol Oncol 90 (2003) 358-365
47. Bauer H.M., Greer C.E., and Manos M. Determination of genital human papillomavirus infection using consensus PCR. In: Herrington C.S., and McGee J.O.D. (Eds). Diagnostic molecular pathology: a practical approach (1992), Oxford University Press, Oxford 132-152
48. Karlsen F., Kalantari M., Jenkins A., et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 34 (1996) 2095-2100
49. Kleter B., van Doorn L.J., Scrauwen L., et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37 (1999) 2508-2517
50. Branca M., Giorgi C., Santini D., et al. Aberrant expression of a novel inhibitor of apoptosis (Survivin) is related to grade of cervical intraepithelial neoplasia (CIN), but does not predict virus clearance after cone or prognosis in cervical cancer. Am J Clin Pathol 124 (2005) 113-121
51. Branca M., Giorgi C., Ciotti M., et al. Down-regulation of nucleoside diphosphate (NDP) kinase nm23-H1 expression is unrelated to high-risk Human papillomavirus (HPV) but associated with progression of CIN and unfavourable prognosis of cervical cancer. J Clin Pathol 59 (2006) 1044-1051
52. Follen M., and Schottenfeld D. Surrogate endpoint biomarkers and their modulation in cervical chemoprevention trials. Cancer 91 (2001) 1758-1776
53. Keating J.T., Ince T., and Crum C.P. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol 8 (2001) 83-92